The Ascites market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Ascites: An Overview
Ascites are defined as an accumulation of more than 25 mL of fluid in the peritoneal cavity. Cirrhosis of the liver is the most common cause of ascites, but other conditions such as heart failure, kidney failure, infection, or cancer can also cause the disease. Ascites are caused by a combination of elevated pressure in the veins running through the liver (portal hypertension) and a decrease in liver function caused by scarring of the liver, i.e., cirrhosis.
Most patients who develop ascites notice abdominal distension and rapid weight gain. Some people also develop swelling of the ankles and shortness of breath from the accumulation of fluid around the lungs.
Ascites related to portal hypertension (cirrhosis, congestive heart failure, Budd-Chiari) is generally greater than 1.1., and ascites caused by other reasons (malignant, pancreatitis) are lower than 1.1.
Ascites Market Key Facts
-
As per the study conducted by Carrier et al. (2014), in France, around 20% of the cases of ascites are not linked to liver cirrhosis.
-
In the United States, in 85% of patients with ascites, cirrhosis is the cause, but 15% have a non-hepatic cause of fluid accumulation. Around 5% of patients had “mixed” ascites or had two or more causes for the ascites, typically cirrhosis plus another reason (Iris et al., 2018).
-
As per the study conducted by Peltekian et al. (2019), males are more likely to suffer from Ascites as compared to females.
Ascites Market Size is expected to increase during the study period owing to the increasing incidence of Ascites and expected approval of emerging therapies.
The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Ascites market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report gives a thorough detail of the Ascites market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Ascites Epidemiology
The epidemiology section covers insights into the historical and current Ascites patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Ascites Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Ascites market or expected to get launched in the market during the study period. The analysis covers Ascites market uptake by drugs, patient uptake by therapies, and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the Ascites Pipeline Development Activities and provides valuable insights about different therapeutic candidates in various stages and the key companies in the market involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Request for Sample PDF Report – https://www.delveinsight.com/sample-request/ascites-market
Ascites Therapeutics Analysis
Some of the companies in the Ascites market include:
-
BioVie
-
Grifols S.A.
-
Noorik Biopharmaceuticals
-
Clover Biopharmaceuticals
And many others.
Ascites therapies covered in the report include:
-
BIV201
-
N-003
-
SCB-313
-
Albutein 20% Injectable Solution
And many more.
Get More Detailed Insights Into the Emerging Therapies & Key Companies – https://www.delveinsight.com/sample-request/ascites-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Ascites Competitive Intelligence Analysis
4. Ascites Market Overview at a Glance
5. Ascites Disease Background and Overview
6. Ascites Patient Journey
7. Ascites Epidemiology and Patient Population
8. Ascites Treatment Algorithm, Current Treatment, and Medical Practices
9. Ascites Unmet Needs
10. Key Endpoints of Ascites Treatment
11. Ascites Marketed Products
12. Ascites Emerging Therapies
13. Ascites Seven Major Market Analysis
14. Attribute Analysis
15. Ascites Market Outlook (7 major markets)
16. Ascites Access and Reimbursement Overview
17. KOL Views on the Ascites Market.
18. Ascites Market Drivers
19. Ascites Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF Report – https://www.delveinsight.com/sample-request/ascites-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Other Latest Reports By DelveInsight
Bevacizumab Biosimilars Insight
DelveInsight’s, “Bevacizumab Biosimilar Insight” report provides comprehensive insights about 40+ companies and 40+ marketed and pipeline drugs in the Bevacizumab Biosimilars landscape. The report also covers the marketed and pipeline drug profiles, including clinical and non-clinical stage products.
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/